BORTEZOMIB belongs to a group of anti-cancer medicines used to treat adult patients with multiple myeloma and mantle cell lymphoma who have received at least one prior therapy. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer it affects several areas of the body, such as the spine, skull, pelvis, and ribs. Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL). It develops when B-cells (also called B-lymphocytes) become abnormal. B-cells are white blood cells that fight infection.
BORTEZOMIB contains 'Bortezomibx' that works by interfering with how proteasomes work, which may cause cancer cells to die and may stop cancer from growing and eventually kills them.
BORTEZOMIB is prescribed by a doctor experienced in the use of medications to treat cancer. It is administered by a healthcare professional as an injection into your vein (intravenously or IV) or under your skin (subcutaneously or SC). BORTEZOMIB must not be administered into your spinal fluid (intrathecally). You may experience nausea, diarrhoea, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), peripheral neuropathy (nerves malfunction), fatigue, neuralgia, anaemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia. Most of these side effects of BORTEZOMIB do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.
To treat your condition effectually, continue taking BORTEZOMIB for as long as your doctor has prescribed. Do not stop the BORTEZOMIB midway. Talk to your doctor before taking BORTEZOMIB if you have allergies or if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), hepatic disorders. Avoid taking BORTEZOMIB if you are pregnant or breastfeeding because this BORTEZOMIB can cause harmful effects on the unborn baby. Both women and men using this BORTEZOMIB should use birth control to avoid pregnancy.
Multiple myeloma and Mantle cell lymphoma.
BORTEZOMIB contains the active substance bortezomib, also-called ‘proteasome inhibitor. Proteasomes play an important role in controlling cell function and growth. By interfering with their function, thereby it can kill cancer cells. BORTEZOMIB is used to treat multiple myeloma (a cancer of the bone marrow) and mantle cell lymphoma (a type of cancer affecting the lymph nodes) in 18 years or older patients. It can be used alone or together with other medicines.
To treat your condition effectually, continue taking BORTEZOMIB for as long as your doctor has prescribed. Do not stop the BORTEZOMIB midway. Talk to your doctor before taking BORTEZOMIB if you have allergies or if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), hepatic disorders. And also, inform your doctor if you have diabetes because this medicine can affect your blood glucose levels. Your doctor may require close monitoring of your blood glucose levels and change your diabetes medicine dose while being treated with BORTEZOMIB. Avoid taking BORTEZOMIB if you are pregnant because this BORTEZOMIB can cause harmful effects on the unborn baby. Both women and men using this BORTEZOMIB should use birth control to avoid pregnancy and for at least six months following treatment. Do not breastfeed during treatment with BORTEZOMIB and four months after your final dose of BORTEZOMIB.
Drug-Drug Interactions: BORTEZOMIB interacts with antifungal medication (ketoconazole), HIV medication (ritonavir), antibiotic medication (rifampicin), epilepsy medications (carbamazepine, phenytoin or phenobarbital), depression medication (St. John’s Wort), and oral antidiabetics.
Drug-Food Interactions: No food interaction was found.
Drug-Disease Interactions: Inform your doctor before taking BORTEZOMIB; it requires close monitoring if you are suffering from peripheral neuropathy (nerves malfunction), hypotension, cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (a low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), and hepatic disorders.
You are recommended to avoid alcohol consumption while taking BORTEZOMIB. It could lead to avoiding unpleasant side effects.
BORTEZOMIB should not be used during pregnancy because it causes harm to the fetus (newborn baby). Both women of childbearing potential and men must use an effective contraception method while taking BORTEZOMIB and at least six months afterwards. Please discuss with your doctor any concerns regarding this.
BORTEZOMIB should not be taken during breastfeeding as it passes into the breastmilk and may harm the nursing baby. It is contraindicated in breastfeeding mothers.
BORTEZOMIB may affect your reactions and your ability to drive. Possible side effects of chemotherapy with BORTEZOMIB may occur, such as nausea and vomiting. If you are affected by these side effects, you should not drive and/or operate machines that require you to be alert.
If you have a history or evidence of liver-related diseases, inform the doctor before prescribing the BORTEZOMIB. Your doctor will weigh the benefits and potential risks before prescribing them.
If you have a history or evidence of kidney-related diseases, inform the doctor before prescribing the BORTEZOMIB. Your doctor will weigh the benefits and potential risks before prescribing them.
BORTEZOMIB should not be used by children below 18 years of age, as efficacy and safety have not been established.
Multiple myeloma, also known as myeloma, is a type of bone marrow cancer it affects several areas of the body, such as the spine, skull, pelvis, and ribs.
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL). It develops when B-cells (also called B-lymphocytes) become abnormal. B-cells are white blood cells that fight infection.
Cancer is a condition where cells in a specific body part grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs.